Elidah

Elidah, Inc. is a medical device company operating in the femtech sector, focused on providing at-home treatments for female urinary incontinence. The Connecticut-based company was founded in March 2014 by the husband-and-wife team, Gloria Kolb (CEO) and Eric Kolb (CTO). Gloria Kolb's personal experience after childbirth, combined with her extensive background in medical device development, including in urology, highlighted a significant gap in the market for effective, non-invasive solutions. This led to the creation of Elidah, a venture backed significantly by grants from the National Science Foundation.

The company's flagship product is ELITONE, an externally worn, FDA-cleared device that treats stress, urge, and mixed urinary incontinence. The business operates on a direct-to-consumer and B2B model, selling its products without a prescription, although it is also covered by Medicare. Revenue is generated through the sale of the ELITONE devices and the accompanying reusable GelPads. The primary market consists of the one in three women who experience bladder leaks, a condition that becomes more prevalent with age.

ELITONE distinguishes itself by being non-intrusive, worn externally on the perineal area under clothing, allowing users to remain active during the 20-minute treatment sessions. The device uses neuromuscular electrical stimulation (NMES) to induce contractions of the pelvic floor muscles, essentially performing Kegel exercises that are stronger and more precise than a person can do on their own. The technology sends patterned electrical signals to contract and strengthen pelvic floor muscles for stress incontinence, and a different signal to calm the bladder muscle for urge incontinence. Clinical studies have demonstrated its effectiveness, with 85% of users reducing pad usage and 75% seeing a clinically significant drop in leakage episodes after six weeks. The company holds multiple patents for its technology and maintains ISO 13485:2016 certification for medical device manufacturing. After initial grant funding, Elidah secured an undisclosed amount in a Series A round in early 2024 to expand its market reach and streamline insurance processes.

Keywords: pelvic floor therapy, urinary incontinence, femtech, medical device, women's health, over-the-counter medical device, bladder control, at-home treatment, neuromuscular electrical stimulation, stress incontinence, urge incontinence, overactive bladder, Gloria Kolb, wearable technology, direct-to-consumer healthcare, FDA-cleared, non-invasive treatment, pelvic health, medical equipment manufacturer, wellness technology